scholarly journals The Relationship Between 18F-FDG Uptake on PET/CT and Markers of Systemic Inflammatory Response in Patients Undergoing Surgery for Intrahepatic Cholangiocarcinoma

2018 ◽  
Vol 39 (1) ◽  
pp. 341-346 ◽  
Author(s):  
SATORU SEO ◽  
TOMOAKI YOH ◽  
KOSHIRO MORINO ◽  
HIROAKI FUJI ◽  
KOJIRO TAURA ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Intrahepatic Cholangiocarcinoma ◽  
Systemic Inflammatory Response ◽  
Fdg Uptake ◽  
Pet Ct ◽  
18F Fdg ◽  
The Relationship

Sa1571 THE RELATIONSHIP BETWEEN FDG UPTAKE, MARKERS OF SYSTEMIC INFLAMMATORY RESPONSE AND OUTCOME IN INTRAHEPATIC CHOLANGIOCARCINOMA

2020 ◽  
Vol 158 (6) ◽  
pp. S-1330-S-1331
Author(s):  
Satoru Seo ◽  
Koshiro Morino ◽  
Tomoaki Yoh ◽  
Ken Fukumitsu ◽  
Takamichi Ishii ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Intrahepatic Cholangiocarcinoma ◽  
Systemic Inflammatory Response ◽  
Fdg Uptake ◽  
The Relationship

Diffusely Increased Bone Marrow 18F-FDG Uptake Is an Independent Predictor of Focal Bone Lesions in Patients with Newly Diagnosed Classical Hodgkin Lymphoma

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5360-5360
Author(s):  
Lars C. Gormsen ◽  
Cecilia Wassberg ◽  
Daniel Molin ◽  
Peter Kamper ◽  
Gunilla Enblad ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Logistic Regression ◽  
Independent Predictor ◽  
Bone Lesions ◽  
Classical Hodgkin Lymphoma ◽  
Fdg Uptake ◽  
Pet Ct ◽  
18F Fdg ◽  
The Relationship ◽  
Initial Staging

Abstract Background: 18F-FDG PET/CT is recommended in the initial staging of patients with classical Hodgkin lymphoma (cHL). Whereas focal 18F-FDG uptake in the skeleton is considered to represent bone involvement, it is still unclear whether diffusely increased 18F-FDG bone marrow uptake (BMU) indicates lymphoma infiltration or merely reflects a state of general inflammation. This retrospective study was therefore performed to study the relationship between pre-therapeutic (PET0) 18F-FDG BMU and the presence of focal bone lesions. Methods: A total of 139 patients (median age 44, range 8-83) referred to PET/CT between 2008 and 2014 for HL staging were included. All PET0 and post-therapeutic (PET2) images were reviewed and evidence of focal bone lesions was recorded (unifocal: ≤2 lesions, multifocal: >2 lesions). In addition, 18F-FDG uptake (SUVmax) was semiquantitatively measured in the vertebral bone marrow (SUVvertebra) and in the right lobe of the liver (SUVliver). BMU was calculated as SUVvertebra/SUVliver. The relationship between focal bone lesions on PET0 and BMU as well as age was subsequently analysed by logistic regression. Results: In total 30/139 (22 %) patients had focal bone lesions at initial staging (10 unifocal, 20 multifocal). BMU at initial presentation was generally increased in all patients when compared with the post-therapeutic PET/CT (PET0: 1.22 +/- 0.03 vs. PET2: 0.95 +/- 0.03, p<0.001). In a logistic regression model diffusely increased BMU at PET0 (p=0.01) as well as age (p=0.01) were both independent predictors of focal bone lesions. Conclusion: Diffusely increased 18F-FDG uptake is an independent predictor of skeletal bone lesions in patients with HL. Evidence of increased BMU might be evaluated as an additional outcome predictor in the pre-therapeutic risk assessment of patients with HL. With the purpose of validating these findings, we will analyze an independent cohort of Swedish cHL patients and joined data from both cohorts will be presented at the meeting. Disclosures No relevant conflicts of interest to declare.

scholarly journals Comparison of serum NEDD-9, CA 15-3, and CEA levels and PET metabolic parameters in breast cancer patients with 18 F-FDG PET / CT

2020 ◽  
Vol 66 (5) ◽  
pp. 673-679
Author(s):  
Esra Arslan ◽  
Hale Aral ◽  
Tamer Aksoy ◽  
Çiğdem Usul Afşar ◽  
Senem Karabulut ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Serum Levels ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Fdg Uptake ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
The Relationship

SUMMARY OBJECTIVE Analyze the over expression of neural precursor cell expressed developmentally down-regulated protein 9 (NEDD-9) deregulated associated with a poor prognosis in various carcinomas. Our objective was to investigate the relationship between the levels of NEDD-9, CA 15-3, and CEA and PET (SUVmax, MTV40, TLG40) with the clinical parameters of patients with breast cancer (BC). METHODS One hundred and eleven patients (82 BC patients who underwent 18F-FDG PET/CT and 29 healthy controls) were evaluated. SUVmax, MTV, and TLG of the primary tumor were compared with the molecular and histopathological subtypes. 18F-FDG, MTV, and TLG were evaluated based on the clinical data, i.e., nodal involvement, distant metastasis, ER and PR status, Ki-67, serum levels of NEDD-9, CA15-3, and CEA. We compared the NEDD-9 in the BC and healthy control groups. RESULTS The mean ± SD of SUVmax in the 82 patients was 13.0 ± 8.6. A statistically significant relationship (p = 0.022) was found between the molecular subtypes and 18F-FDG uptake. The relationship between 18F-FDG uptake and TLG measured in patients <50 years, ER-PR negativity, and HER2 positivity were statistically significant (p=0.015, 0.007, 0.046, and 0.001, respectively). MTV40, TLG40, and CA 15-3 in metastatic patients were statistically significant (p=0.004, 0.005, and 0.003, respectively). NEDD-9 in the BC group was significantly higher than in the healthy group (p=0.017). There was a positive correlation between SUVmax and Ki67 and CA 15-3; MTV40 and CEA; CA 15-3, CEA, SUVmax, and MTV40; a negative correlation was found between CEA, TLG40, and age. CONCLUSION The use of SUVmax, MTV40, and TLG40 parameters with NEDD-9 and tumor markers has been shown to provide a high diagnostic, predictive, and prognostic value for the management of BC. This is considered to be the basis of interventions focused on the treatment objectives related to NEDD-9.

18F-FDG Uptake on PET/CT in Transposed Ovaries

2006 ◽  
Vol 186 (1) ◽  
pp. 267-268 ◽  
Author(s):  
R. Zissin ◽  
E. Even-Sapir
Keyword(s):  
Fdg Uptake ◽  
Pet Ct ◽  
18F Fdg

scholarly journals Impacts of time interval on 18F-FDG uptake for PET/CT in normal organs

Medicine ◽  
2018 ◽  
Vol 97 (45) ◽  
pp. e13122 ◽  
Author(s):  
Rang Wang ◽  
Haotian Chen ◽  
Chengzhong Fan
Keyword(s):  
Time Interval ◽  
Fdg Uptake ◽  
Pet Ct ◽  
18F Fdg

scholarly journals OP0063 SINGLE CENTRE EXPERIENCE OF THE CLINICAL SPECTRUM, AETIOLOGIES AND MANAGEMENT OF NON-INFECTIOUS AORTITIS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 34.1-34
Author(s):  
R. S. Andev ◽  
N. Ahmad ◽  
A. Verdiyeva ◽  
R. Luqmani ◽  
S. Dubey
Keyword(s):  
Systemic Inflammatory Response Syndrome ◽  
Inflammatory Response ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Systemic Inflammatory Response ◽  
Aortic Aneurysms ◽  
Large Vessel ◽  
Complication Rates ◽  
Pet Ct ◽  
The Mean

Background:Aortitis, a rare form of large vessel vasculitis, may occur in the context of a primary systemic vasculitis, as a part of systemic autoimmune disease or in isolation. The evidence and guidelines to diagnose, manage and monitor aortitis remain limited. However, PET CT and vascular MRI scans have facilitated our ability to make the diagnosis more readily. The optimal management strategy and complication rates remain uncertain.Objectives:Our aim was to explore the clinical, laboratory and radiological features of aortitis. We sought to review the management and complications of this illness by collecting detailed information on the outcomes and treatments used, including disease modifying agents (DMARDs) and biologics.Methods:Patients diagnosed with aortitis since 2006 that had been managed in a single tertiary centre were identified using the Rheumatology Assessment Database Innovation in Oxford (RHADIO). Their medical notes were retrospectively reviewed using a local electronic patient record system and the following information was obtained: demographics, underlying risk factors, imaging and laboratory results (including biopsy reports if available), management and outcome.Results:We identified 155 patients who met the inclusion criteria. There was a female preponderance of 57.4% (n=89). At the time of diagnosis, the average age was 69 (range 30-92) and the mean symptomatology length prior to diagnosis was 12 months (range 0-120). The majority of patients (60.4%, n=94) had aortitis secondary to giant cell arteritis (GCA), isolated aortitis was identified in 29.7% (n=46) and IgG4-related disease aortitis was uncommon (2.6%, n=4). Those with cranial GCA-like symptoms were diagnosed on average 3.9 months before those who presented differently (10.1 months versus 14.0 months).Common presentations comprised: systemic inflammatory response syndrome (49.0%, n=76), cranial GCA-like symptoms (26.5%, n=41) and unexplained weight loss (24.5%, n=38). Importantly, 18.7% (n=29) of patients presented with ischaemic symptoms that included angina, TIAs/strokes and claudication. Aortic dissection was the primary presentation for 6.5% (n=10) of patients.At presentation, the mean CRP was 84 mg/L (range 1-249) and the ESR was 72 mm/hr (range 2-164). Most (73.5%, n=114) had diagnostic PET CT changes. For those patients with GCA, diagnostic ultrasound changes were seen in 27.7% (n=26).Nearly all were treated with prednisolone (92.3%, n=143) and all but 8 (5.1%) received a DMARD at some point. Methotrexate was the most commonly used DMARD (93.9%, n=138), followed by leflunomide (22.3%, n=35) and azathioprine (19.1%, n=28). Cyclophosphamide was used in 23.8% of patients (n=38) and 15 patients (9.7%) received tocilizumab.Around a third (34.1% n=53/155) had received at least two DMARDs during their treatment course. On average, patients required 3.46 drugs to manage their aortitis. Those who relapsed (43.2%, n=67) were more likely to have GCA (65.7%, n=44).Vascular sequelae were present in 37.4% (n=58). The most common complications were ischaemic in nature with stroke/TIA and claudication reported in 16.8% (n=26). Aortic aneurysms were recorded in 11.6% (n=18) of cases and 5.1% (n=8) developed dissections despite being on treatment for their aortitis. One patient developed renal infarcts and ischaemic bowel leading to intestinal failure because of florid vasculitis.Conclusion:Aortitis has a varied presentation with systemic inflammatory response syndrome being the most common. Delayed diagnosis remains a problem and especially for those with non-GCA related aortitis, which is likely to contribute to the risk of subsequent vascular complications. Vascular events including dissection are common, many of which could be preventable, emphasising the importance of early diagnosis and good disease control.References:[1]Koster M et al. Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology [Internet]. 2018 Feb 1;57(suppl_2):ii32–42. Available from: https://doi.org/10.1093/rheumatology/kex424Disclosure of Interests:None declared

scholarly journals Characteristics and Clinical Value of 18F-FDG PET/CT in the Management of Adult-Onset Still’s Disease: 35 Cases

2021 ◽  
Vol 10 (11) ◽  
pp. 2489
Author(s):  
Josselin Brisset ◽  
Yvan Jamilloux ◽  
Stephanie Dumonteil ◽  
Guillaume Lades ◽  
Martin Killian ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Lymph Node ◽  
Differential Diagnoses ◽  
Adult Onset Still’S Disease ◽  
Still’S Disease ◽  
Clinical Value ◽  
Fdg Uptake ◽  
Pet Ct ◽  
18F Fdg ◽  
Adult Onset Still's Disease

While the diagnosis of adult-onset Still’s disease (AOSD) involves the exclusion of differential diagnoses, the characteristics and value of 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography coupled with CT (PET/CT) in the management of AOSD remain poorly known. Our retrospective study included patients from four centers, fulfilling Yamaguchi or Fautrel criteria, who underwent a PET/CT during an active AOSD. Thirty-five patients were included. At the time of PET/CT, the Yamaguchi criteria were met in 23 of 29 evaluable cases. PET/CT showed bone marrow (74.3%), lymph node (74.3%), and splenic (48.6%) FDG uptake. Despite arthralgia or arthritis in most patients, joints were rarely the sites of 18F-FDG accumulation. The spatial distribution of 18F-FDG uptake was nonspecific, and its intensity could be similar to malignant disease. Lymph node or bone marrow biopsy was performed after PET/CT in 20 patients (57.1%). The intensity of bone marrow; splenic and lymph node hypermetabolism appeared to be correlated with disease activity. Abnormal PET/CT in the cervical lymph nodes and age ≥ 60 years seemed to be predictive factors for monocyclic evolution. The clinical value of PET/CT is not in direct diagnosis; but as an aid in excluding differential diagnoses by searching for their scintigraphic features and guiding biopsy.

scholarly journals Quantitative, Dynamic 18F-FDG PET/CT in Monitoring of Smoldering Myeloma: A Case Report

Diagnostics ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 649
Author(s):  
Christos Sachpekidis ◽  
Matthias Türk ◽  
Antonia Dimitrakopoulou-Strauss
Keyword(s):  
Bone Marrow ◽  
Plasma Cells ◽  
Autologous Transplantation ◽  
Standardized Uptake Value ◽  
Focal Lesions ◽  
Fdg Uptake ◽  
Pet Ct ◽  
18F Fdg ◽  
Smoldering Myeloma

We report on a 52-year-old patient with an initial diagnosis of smoldering myeloma (SMM), who was monitored by means of dynamic and static positron emission tomography/computed tomography (PET/CT) with the radiotracer 1⁸F-fluorodeoxyglucose (18F-FDG). Baseline PET/CT revealed no pathological signs. Six months later, a transition to symptomatic, multiple myeloma (MM) was diagnosed. The transition was not accompanied by focal, hypermetabolic lesions on PET/CT. However, a diffusely increased 18F-FDG uptake in the bone marrow, accompanied by a marked increase of semi-quantitative (standardized uptake value, SUV) and quantitative, pharmacokinetic 18F-FDG parameters, was demonstrated. After successful treatment, including tandem autologous transplantation, the diffuse uptake in the bone marrow as well as the semi-quantitative and quantitative parameters showed a marked remission. This response was also confirmed by the clinical follow-up of the patient. These findings suggest that in MM a diffuse 18F-FDG uptake in the bone marrow may indeed reflect an actual bone marrow infiltration by plasma cells. Moreover, SUV values and kinetic parameters, not only from myeloma lesions but also from random bone marrow samples, may be used for MM monitoring. This could be particularly helpful in the follow-up of myeloma patients negative for 18F-FDG-avid focal lesions.

Sign in / Sign up

Export Citation Format

Share Document